Zoomed Image
  • Flixotide 50mcg Evohaler 120 Doses

Flixotide 50mcg Evohaler 120 Doses

Flixotide 50 micrograms Evohaler is a pressurised inhalation suspension, delivering 50 micrograms of fluticasone propionate per actuation. Therapeutic indications: Fluticasone propionate given by inhalation offers prophylactic treatment for asthma. Adults: Mild asthma: Patients requiring intermittent symptomatic bronchodilator asthma medication on a regular daily basis. Moderate asthma: Patients with unstable or worsening asthma despite prophylactic therapy or bronchodilator alone. Severe asthma: Patients with severe chronic asthma and those who are dependent on systemic corticosteroids for adequate control of symptoms. On introduction of inhaled fluticasone propionate many of these patients may be able to reduce significantly, or to eliminate, their requirement for oral corticosteroids. Children: Any child who requires prophylactic medication, including patients not controlled on currently available prophylactic medication.
How to use
Flixotide Evohaler is for oral inhalation use only. Flixotide Evohaler may be used with a Volumatic spacer device by patients who find it difficult to synchronise aerosol actuation with inspiration of breath. Typical Adult Starting Doses: For patients with mild asthma, a typical starting dose is 100 micrograms twice daily. In moderate and more severe asthma, starting doses may need to be 250 to 500 micrograms twice daily. Where additional clinical benefit is expected, doses of up to 1000 micrograms twice daily may be used. Initiation of such doses should be prescribed only by a specialist in the management of asthma (such as a consultant physician or general practitioner with appropriate experience). The dose should be titrated down to the lowest dose at which effective control of asthma is maintained Typical starting doses for children over 4years of age: 50 to 100 micrograms twice daily. Many children's asthma will be well controlled using the 50 to 100 microgram twice daily dosing regime. For those patients whose asthma is not sufficiently controlled, additional benefit may be obtained by increasing the dose up to 200 micrograms twice daily.
Patients' inhaler technique should be checked regularly to make sure that inhaler actuation is synchronised with inspiration to ensure optimum delivery to the lungs. During inhalation, the patient should preferably sit or stand. The inhaler has been designed for use in a vertical position. Sudden and progressive deterioration in asthma control is potentially life-threatening and consideration should be given to increasing corticosteroid dosage. In patients considered at risk, daily peak flow monitoring may be instituted. Flixotide Evohaler is not designed to relieve acute symptoms for which an inhaled short-acting bronchodilator is required. Patients should be advised to have such rescue medication available.